H. TÜRK, M. YOLDAŞ, H. TARHAN, S. ÜN, O KOCA

Nadir bir prostat kanseri: Primer taşlı yüzük hücreli adenokarsinom

Prostatın primer taşlı yüzük hücreli karsinomu nadir görülen bir histolojik varyanttır. Genellikle mide, kolon, pankreas ve daha nadir olarak mesaneden kaynaklanır. Klasik prostat adenokarsinomlarına göre daha kötü prognoza sahiptir. Primer prostatın taşlı yüzük hücreli adenokarsinom tanısını koymadan önce, bu adenokarsinomu taklit eden bazı durumların dışlanması gerekir. Bu yazıda, kısa sürede yükselen prostat spesifik antijen (PSA) nedeniyle kemoterapi başlanan prostatın taşlı yüzük hücreli adenokarsinomu olgusu sunulmaktadır.

A rare prostate cancer: Primary signet ring cell adenocarcinoma

Primary signet ring cell adenocarcinoma of the prostate is a rare histologic variant. It usually originates from stomach, colon, pancreas and rarely from the bladder. Compared with usual adenocarcinomata of prostate, it has a worse prognosis. Before diagnosing signet ring cell adenocarcinoma of the prostate, we need to eliminate some conditions that imitate adenocarcinoma. In this article, a patient with primary signet ring cell adenocarcinoma of the prostate is presented in which chemotherapy was given due to the rapid rising prostate specific antigen (PSA) level.

PDF

___

1. Fujita K, Sugao H, Gotoh T, Yokomizo S, Itoh Y. Primary signet ring cell carcinoma of the prostate: Report and review of 42 cases. Int J Urol 2004;11(3):178-81.
2. Kwon W, Oh TH, Ahn SH, Lee JW, Park SC. Primary signet ring cell carcinoma of the prostate. Can Urol Assoc J 2013;7(11- 12):768-71.
3. Skodras G, Wang J, Kragel PJ. Primary prostatic signet-ring cell carcinoma. Urology 1993;42(3):338-42.
4. Smith C, Feddersen RM, Dressler L, McConnell T, Milroy T, Smith AY. Signet ring cell adenocarcinoma of prostate. Urology 1994;43(3):397-400.
5. Kuroda N, Yamasaki I, Nakayama H, et al. Prosatatic signet-ring cell carcinoma: Case report and literature review. Pathol Int 1999;49(5):457-61.
6. Guerin D, Hasan N, Keen CE. Signet ring cell differentiation in adenocarcinoma of the pr ostate: Study of five cases. Histopathology 1993;22(4):367-71.
7. Akagashi K, Tanda H, Kato S, et al. Signet-ring cell carcinoma of the prostate effectively treated with maximal androgen blockade. Int J Urol 2003;10(8):456-8.
8. Roldán AM, Núñez NF, Grande E, García AÁ, Antón-Aparicio LM. Primary signet ring cell carcinoma of the prostate with bone metastasis with ımpressive response to folfox and cetuximab. Clin Gen Cancer 2012;10(3):199-201.
9. Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH. Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate. Acta Oncol 2007;46(8):1195-7.
10. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: Pathologic criteria and clinical significance. Mod Pathol 1997;10(6):612-29.
11. Torbenson M, Dhir R, Nangia A, Becich MJ, Kapadia SB. Prostatic carcinoma with signet ring cells: A clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol 1998;11(6):552-9.